Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Dutkowski R.

J Antimicrob Chemother. 2010 Apr;65 Suppl 2:ii11-ii24. doi: 10.1093/jac/dkq012. Review.

2.

Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir.

Reddy D.

J Antimicrob Chemother. 2010 Apr;65 Suppl 2:ii35-ii40. doi: 10.1093/jac/dkq014. Review.

3.

Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.

Renaud C, Kuypers J, Englund JA.

J Clin Virol. 2011 Oct;52(2):70-8. doi: 10.1016/j.jcv.2011.05.019. Epub 2011 Jun 17. Review.

PMID:
21684202
4.

The epidemiology and spread of drug resistant human influenza viruses.

Hurt AC.

Curr Opin Virol. 2014 Oct;8:22-9. doi: 10.1016/j.coviro.2014.04.009. Epub 2014 May 24. Review.

PMID:
24866471
5.

Influenza virus susceptibility and resistance to oseltamivir.

Aoki FY, Boivin G, Roberts N.

Antivir Ther. 2007;12(4 Pt B):603-16. Review.

PMID:
17944268
6.

Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.

Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dutkowski R.

Adv Ther. 2011 Nov;28(11):927-59. doi: 10.1007/s12325-011-0072-7. Epub 2011 Nov 1. Review.

PMID:
22057727
7.

Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.

Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R.

Infect Disord Drug Targets. 2013 Feb;13(1):34-45. Review.

PMID:
23675925
8.

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

Ikematsu H, Kawai N.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Review.

PMID:
21973296
9.

Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014).

Chan-Tack KM, Kim C, Moruf A, Birnkrant DB.

Antivir Ther. 2015;20(5):561-4. doi: 10.3851/IMP2944. Epub 2015 Feb 10. Review.

PMID:
25667992
10.

Influenza viruses resistant to neuraminidase inhibitors.

Nitsch-Osuch A, Brydak LB.

Acta Biochim Pol. 2014;61(3):505-8. Epub 2014 Sep 8. Review.

11.

Safety of oseltamivir in pregnancy: a review of preclinical and clinical data.

Donner B, Niranjan V, Hoffmann G.

Drug Saf. 2010 Aug 1;33(8):631-42. doi: 10.2165/11536370-000000000-00000. Review.

PMID:
20635821
12.

Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ.

BMJ. 2014 Apr 9;348:g2545. doi: 10.1136/bmj.g2545. Review.

13.

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.

Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D.

Drug Saf. 2008;31(12):1097-114. doi: 10.2165/0002018-200831120-00006. Review.

PMID:
19026027
14.

Effect of Oseltamivir (Tamiflu®) for the Prevention and Treatment of Influenza During an Influenza Pandemic [Internet].

Mørland B, Brantsæter AB, Fuglesang JE, Haaheim LR, Løvoll Ø, Salmén R, Sjursen H, Kristiansen IS, Wisløff T, Ørjasæter Elvsaas IK, Nilsen E.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005.

15.

Oseltamivir for influenza in pregnancy.

Beigi RH, Venkataramanan R, Caritis SN.

Semin Perinatol. 2014 Dec;38(8):503-7. doi: 10.1053/j.semperi.2014.08.015. Epub 2014 Oct 1. Review.

16.

Safety and pharmacology of oseltamivir in clinical use.

Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P.

Drug Saf. 2003;26(11):787-801. Review.

PMID:
12908848
17.

Immunization and treatment updates: 2016-2017 influenza season.

de St Maurice A, Halasa N.

Pediatr Transplant. 2017 Feb;21(1). doi: 10.1111/petr.12884. Review.

PMID:
28127885

Supplemental Content

Support Center